Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes

被引：0
|
作者：
Kovacs, C. S. [1 ]
Seshiah, V. [2 ]
Merker, L. [3 ]
Christiansen, A. Vedel [4 ]
Roux, F. [5 ]
Salsali, A. [6 ]
Kim, G. [6 ]
Stella, P. [6 ]
Woerle, H. J. [6 ]
Broedl, U. C. [6 ]
机构：
[1] Mem Univ Newfoundland, Hlth Sci Ctr, St John, NF A1C 5S7, Canada
[2] Diabet Care & Res Inst, Chennai, Tamil Nadu, India
[3] Diabet & Nierenzentrum, Dormagen, Germany
[4] Boehringer Ingelheim Danmark AS, Copenhagen, Denmark
[5] Boehringer Ingelheim France, Reims, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [1] Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1773 - 1788
  • [2] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [3] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [4] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A291 - A291
  • [5] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A273 - A273
  • [6] Empagliflozin as add-on to metformin in people with Type 2 diabetes
    Merker, L.
    Haering, H-U.
    Christiansen, A. V.
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 (12) : 1555 - 1567
  • [7] Empagliflozin as add-on to metformin plus sulfonylurea in patients with Type 2 diabetes
    Haering, H. U.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [8] Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Haering, Hans-Ulrich
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) : 82 - 90
  • [9] Effects of Pioglitazone Add-On to Gliclazide and Metformin on Glycemic Control in Patients with Type 2 Diabetes
    Al-Azzam, Sayer I.
    AlOmari, Mousa
    Khader, Yousef S.
    AlMahasneh, Fatimah A.
    Muflih, Suhaib M.
    Altawalbeh, Shoroq
    ENDOCRINE RESEARCH, 2012, 37 (01) : 7 - 11
  • [10] Empagliflozin twice daily versus once daily as add-on to metformin in patients with type 2 diabetes
    Ross, S.
    Hamer, C.
    Cescutti, J.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S345 - S345
12345